Posted by AGORACOM-JC
at 12:09 PM on Monday, December 14th, 2020
Else Nutrition Holdings Inc. (BABY: TSXV) (BABYF: OTCQX) (0YF: FSE) is the award winning, plant-based nutrition company for small cap investors. The shift towards plant-based alternatives has opened the food market to new players, and created an opportunity for fast growth in a rapidly expanding space. Else has fully grasped at this opportunity as seen below.
Highlights include:
$CAD 30 Million In Cash
Launched 1st Commercial Product Into US Market
Backed By A $2.7 Billion Dollar Global Nutrition Company;
MOU For International Distribution Of Products
“Best Health” Award At Global Food Innovation Summit In Milan;
Awarded Patents In 22 Countries, 44 Countries Pending;
Executives & Advisors From Globally Renowned Companies & Institutions
Distribution agreement with one of the largest and most well regarded national fresh, organic and specialty food distributors in North America
Received key Clean Label Certifications for Toddler Nutrition Product
Received Key USDA Organic Certification
Else Nutrition’s Complete Nutrition for Toddlers ranked Top-Selling Product on Amazon’s Hot New Releases in Baby and Toddler Formula Category
Posted by AGORACOM-JC
at 11:14 AM on Monday, December 14th, 2020
Under the arrangement, Allied’s Tactical Relief™ branded products will be sold in licensed dispensaries across California.
Through their extensive distribution network, Hollister’s other brands have brought in excess of $40 million revenue between January and December 2020.
Allied has contributed the veteran brand, artwork, logos, packaging design and marketing for all Tactical Relief™ products.
Hollister has completed all aspects of production and procurement of underlying materials.
Allied will be supporting the marketing and brand presence with authentic veteran representation.
KELOWNA, British Columbia, Dec. 14, 2020 — Allied Corp. (“Allied”) ( OTCQB: ALID ) – an international medicinal cannabis company focused on creating and providing targeted cannabinoid health solutions to address PTSD, anxiety, stress and inflammation of the body is pleased to follow on the press release of June 26, 2020 announcing a distribution deal with Hollister Biosciences. Under the arrangement, Allied’s Tactical Relief™ branded products will be sold in licensed dispensaries across California. Through their extensive distribution network, Hollister’s other brands have brought in excess of $40 million revenue between January and December 2020. This statement is supported by Hollister’s press release of Dec 09, 2020.
Allied has contributed the veteran brand, artwork, logos, packaging design and marketing for all Tactical Relief™ products. Hollister has completed all aspects of production and procurement of underlying materials. Allied will be supporting the marketing and brand presence with authentic veteran representation.
“We are excited to partner with Hollister to bring our innovative and differentiated line up of quality Tactical Relief™ products to consumers in Hollister’s distribution network. Hollister has a proven track record of bringing successful products to market. The potential market for Tactical Relief™ products in the states that Hollister distributes to is substantial. Together, we hope to build a solid recurring revenue pipeline,” said Calum Hughes, Founder & CEO of Allied Corp.
“Tactical Relief™ is Allied’s flagship brand targeting PTSD, a debilitating condition that is all too common amongst people who are often serving in the front lines,” said Adam Smith, a Green Beret, veteran, and US representative at Allied. “We are excited to be partnering with Hollister to greatly expand Tactical Relief’s reach to those suffering from the serious effects of PTSD.”
“We are very excited to be launching Tactical Relief™ to Veterans, 1 st responders, and others suffering from PTSD through our distribution network,” said Carl Saling, Founder, CEO and Director of Hollister Biosciences Inc.
About Allied Corp. Allied Corp. is an international medical cannabis production company with a mission to address today’s medical issues by researching, creating and producing targeted cannabinoid health solutions. Allied Corp. uses an evidence-informed scientific approach to make this mission possible, through cutting-edge pharmaceutical research and development, innovative plant-based production and unique development of therapeutic products.
About Tactical Relief: https://tacticalrelief.com/cbdproducts/ Tactical Relief™ is a lifestyle brand that focuses on the licensing, development, and marketing of products around its life-style message for those suffering from symptoms of post-traumatic stress and traumatic brain injury. Specifically, Tactical Relief™ provides products and resources to veterans and first responders.
About Hollister Biosciences Inc. Hollister Biosciences Inc. ( CSE: HOLL ) is a California based vertically integrated cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality California-grown cannabis and hemp products. Hollister uses a vertically integrated, high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Cannabis Co. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker.”
Forward-Looking Statements: This press release contains “forward-looking information” within the meaning of applicable securities laws in Canada or “forward-looking statements” made pursuant to the “safe harbour” provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking information”). Forward-looking information may relate to the Company’s future outlook and anticipated events, plans or results, and may include information regarding the Company’s objectives, goals, strategies, future revenue or performance and capital expenditures, and other information that is not historical information. Forward-looking information can often be identified by the use of terminology such as “believe,” “anticipate,” “plan,” “expect,” “pending,” “in process,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions. The forward-looking information contained in this press release is based on the Company’s opinions, estimates and assumptions in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward looking statements in this press release include the following: that Allied is leveraging the conditions in its Colombia grow operation and future Kelowna location to support its Research and Development efforts; that Allied is making important strides forward to position itself as a leader in the medical cannabis space, that Allied intends to make a series of proposed trademark and other intellectual property protection filings, as part of the Company’s Intellectual Property and Pharma Development (IP&PD) Strategy, statements respecting the joint development, manufacturing, and introduction of TACTICAL RELIEF™ branded products, and the use of proceeds from the offering of convertible notes.
There can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Risk factors that could cause actual results to differ materially from forward-looking information in this release include: the Company’s exposure to legal and regulatory risk; the effect of the legalization of adult-use cannabis in Canada and Colombia on the medical cannabis industry is unknown and may significantly and negatively affect the Company’s medical cannabis business; that the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis are not as currently expected; that adverse changes or developments affecting the Company’s main or planned facilities may have an adverse effect on the Company; that the medical cannabis industry and market may not continue to exist or develop as anticipated or the Company may not be able to succeed in this market; risks related to completion of the greenhouse construction in Colombia, risks related to market competition; risks related to the proposed adult-use cannabis industry and market in Canada and Colombia including the Company’s ability to enter into or compete in such markets; that the Company has a limited operating history and a history of net losses and that it may not achieve or maintain profitability in the future; risks related to the Company’s current or proposed international operations; risks related to future third party strategic alliances or the expansion of currently existing relationships with third parties; that the Company may not be able to successfully identify and execute future acquisitions or dispositions or successfully manage the impacts of such transactions on its operations; risks inherent to the operation of an agricultural business; that the Company may be unable to attract, develop and retain key personnel; risks resulting from significant interruptions to the Company’s access to certain key inputs such as raw materials, electricity, water and other utilities; that the Company may be unable to transport its cannabis products to patients in a safe and efficient manner; risks related to recalls of the Company’s cannabis products or product liability or regulatory claims or actions involving the Company’s cannabis products; risks related to the Company’s reliance on pharmaceutical distributors; that the Company, or the cannabis industry more generally, may receive unfavourable publicity or become subject to negative consumer or investor perception; that certain events or developments in the cannabis industry more generally may impact the Company’s reputation or its relationships with customers or suppliers; that the Company may not be able to obtain adequate insurance coverage in respect of the risks that it faces, that the premiums for such insurance may not continue to be commercially justifiable or that there may be coverage limitations and other exclusions which may result in such insurance not being sufficient; that the Company may become subject to liability arising from fraudulent or illegal activity by its employees, contractors, consultants and others; that the Company may experience breaches of security at its facilities or losses as a result of the theft of its products; risks related to the Company’s information technology systems; that the Company may be unable to sustain its revenue growth and development; that the Company may be unable to expand its operations quickly enough to meet demand or manage its operations beyond their current scale; that the Company may be unable to secure adequate or reliable sources of necessary funding; risks related to, or associated with, the Company’s exposure to reporting requirements; risks related to conflicts of interest; risks related to fluctuations in foreign currency exchange rates; risks related to the Company’s potential exposure to greater-than-anticipated tax liabilities; risks related to the protection and enforcement of the Company’s intellectual property rights, or the intellectual property that it licenses from others; that the Company may become subject to allegations that it or its licensors are in violation of the intellectual property rights of third parties; that the Company may not realize the full benefit of the clinical trials or studies that it participates in; that the Company may not realize the full benefit of its licenses if the licensed material has less market appeal than expected and the licenses may not be profitable; as well as any other risks that may be further described in and the risk factors discussed in the Company’s continuous disclosure including its Management’s Discussion and Analysis sections in its Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K filed under the Company’s profile at www.sec.gov.
Although management has attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking information in this presentation, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers and viewers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this release represents the Company’s expectations as of the date of this release or the date indicated, regardless of the time of delivery of the presentation. The Company disclaims any intention, obligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required under applicable securities laws.
Posted by AGORACOM-JC
at 8:27 AM on Monday, December 14th, 2020
A 400% increase in cultivation and production capacity is expected as they expand into their new facility
“This facility is going to resonate through the industry, not only in California, but I believe worldwide,” says CEO, Bob Blink.
TransCanna Holdings seeks to contribute to the cannabis industry as a strategic vertically integrated acquisition company. TransCanna is currently transforming. They’re now scaling the company to leverage their vertically integrated cannabis facility in Modesto California. In fact, it will be one of the largest cannabis facilities in the State. It will also have access to over 39 million residents and 240 million visitors per year. Further, the facitlity will be over 20 times larger than their current site.
“We’re really excited about phase one financing because it’s going to enable us to realize a four hundred percent increase in cultivation and production capacity,” says General Manager, Alan Applonie.
All of TransCanna’s product in its original site is sold out until March of 2021. So, bringing this additional capacity online will allow the company to deliver the product to consumers.
“With Phase One expansion plans nearly complete, TransCanna is prepared to seize on some massive opportunities,” says Blink.
In addition, the company recently acquired two California companies, a high-end edible producer Soldaze and a premium indoor cultivator and distributer Lyfted Farms. Combining one of the largest cannabis production facilities with the brands and management teams from these acquisitions will make TransCanna a major opportunity for investors and partners alike.
Posted by AGORACOM-JC
at 7:41 AM on Monday, December 14th, 2020
Announced a follow-on order for approximately C$ 1.1 million with a key U.S. military customer to expand use of the Company’s TASCS IFM system in military exercises, a key precursor to wider adoption
contract is for application of the TASCS IFM system on the 81mm mortar platform, which transforms it into a “smart” weapon system with greater accuracy and faster response time, improving soldier survivability and operational effectiveness.
Work under the order is scheduled to commence immediately.
Founder, President and CEO Jeff MacLeod commented that, “This marks another key validating milestone in a market where TASCS IFM on the 81mm mortar alone could ultimately be worth up to C$120 million in the U.S. and another C$400 million worldwide, given the large installed base of 81mm mortars in service with so many NATO and allied military forces.”
Ottawa, Ontario–(December 14, 2020) – KWESST Micro Systems Inc. (TSXV: KWE) (“KWESST” or “the Company”) today announced a follow-on order for approximately C$ 1.1 million with a key U.S. military customer to expand use of the Company’s TASCS IFM system in military exercises, a key precursor to wider adoption.
The contract is for application of the TASCS IFM system on the 81mm mortar platform, which transforms it into a “smart” weapon system with greater accuracy and faster response time, improving soldier survivability and operational effectiveness. Work under the order is scheduled to commence immediately.
KWESST Founder, President and CEO Jeff MacLeod commented that, “This marks another key validating milestone in a market where TASCS IFM on the 81mm mortar alone could ultimately be worth up to C$120 million in the U.S. and another C$400 million worldwide, given the large installed base of 81mm mortars in service with so many NATO and allied military forces.”
KWESST previously announced the completion of an earlier two-phase initial contract with the same customer that marked the introduction of TASCS IFM on 81mm mortars in military exercises. “It is very encouraging to see the accelerated pace at which this important customer is expanding the use of TASCS IFM in its field exercises, and their confidence in KWESST,” added MacLeod. “It is an honor to be working with them to enhance soldier survivability and effectiveness, which is our core mission.”
As previously announced, the TASCS IFM system has attracted interest from other NATO forces who have requested proposals from KWESST, which the Company is currently actioning. “The fact that the TASCS IFM confers so many modernization advantages without any modification to weapon platforms or munitions is a huge attraction,” said MacLeod.
He added that, “The 81mm mortar is just one of many different weapon platforms that can be transformed into a smart system with TASCS IFM, providing soldiers on the ground with real-time networked situational awareness and precision targeting information.” Accordingly, KWESST is pursuing additional global markets for the TASCS IFM, which can also work on platforms such as: 60mm mortars; grenade launchers; sniper rifles; drones; electronic decoys; and more, with a total addressable market of more than C$1 billion.
About KWESST
KWESST develops and commercializes high-value ultra-miniaturized technology applications that make a critical difference to the safety and operational effectiveness of personnel in the defence and security industries. The company’s current portfolio of unique proprietary offerings include: its signature TASCSTM (Tactical and Situational Control System) for real-time awareness and targeting information from any source (including drones) streamed directly to users’ smart devices and weapons; the autonomous GreyGhostTM soldier-portable micro drone missile system that defends against small hostile drones including swarms using high-speed kinetic impact; a Ground Laser Defence system to counter the emerging threat of weaponized lasers against personnel; and, the PhantomTM electronic battlefield decoy system to mask the electromagnetic signature of friendly forces with decoy signatures at false locations to deceive and confuse adversaries. All systems can operate stand-alone or integrate seamlessly with OEM products and battlefield management systems including Frontline, Edge, Killswitch and ATAK (Android Tactical Assault Kit) among others. KWESST also has developmental “smart ordnance” projects including its “Shot Counter” system, which records the number and type of rounds fired, for optimized firearms maintenance and performance. The Company is headquartered in Ottawa, Canada, with representative offices in Washington, DC, London, UK and Abu Dhabi, UAE. KWESST trades on the TSX Venture Exchange under the symbol KWE.
This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the plans and operations of KWESST. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. KWESST disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Posted by AGORACOM-JC
at 7:37 AM on Monday, December 14th, 2020
Film Bubble Provides Another Major Opportunity As Spin-Off Of Successional NCAA Venue Bubble and Travel Bubble Projects
Announced the successful launch of its first “Film Bubble” for a major motion picture (“MMP1”) that is scheduled to commence filming in January 2021.
The name of the film and the starring actors will remain confidential until the commencement of filming.
launch of the Film Bubble for MMP1 is the result of a partnership agreement with Draganfly Inc (DFLY:CSE).
Draganfly’s Safe Set Solutions for the global film and TV production industry is a ground-based technology that uses symptom pre-screening, elevated body temperature measurement, and social distancing digital display to help ensure that everybody on the set is safe.
VANCOUVER, British Columbia, Dec. 14, 2020 — Loop Insights Inc. (MTRX:TSXV) (RACMF:OTCQB) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated venue tracing to the brick and mortar space, is pleased to announce the successful launch of its first “Film Bubble” for a major motion picture (“MMP1”) that is scheduled to commence filming in January 2021. The name of the film and the starring actors will remain confidential until the commencement of filming.
The launch of the Film Bubble for MMP1 is the result of a partnership agreement with Draganfly Inc (DFLY:CSE). Draganfly’s Safe Set Solutions for the global film and TV production industry is a ground-based technology that uses symptom pre-screening, elevated body temperature measurement, and social distancing digital display to help ensure that everybody on the set is safe.
Loop Insights CEO Rob Anson stated, “The addition of Dragonfly’s Safe Set Solutions to our Venue Bubble Platform creates an instant and powerful Film Bubble solution for an industry that has suffered catastrophic losses in 2020 and can’t afford to stay shut down for a minute longer. We are extremely proud to have jointly delivered a solution to the film industry that will allow them to safely get their crews, actors, and supporting infrastructure back to work and generating prosperity, the ripple effects of which reverberate around the world.”
Draganfly CEO Cameron Chell stated, “Partnering with Loop Insights to combine our respective technologies into Loop’s Venue Bubble solution is a powerful and significant step to help all industries and most immediately Hollywood and the global film industry safely ramp up production. Film industry investors, insurance companies, unions, and guilds are all seeking this type of solution to keep workers safe and protect their investments.”
FILM AND TV STUDIOS SEEK FAST AND RELIABLE TESTING SOLUTIONS TO RESUME SAFE OPERATIONS AND MITIGATE BILLIONS IN LOSSES
Total earnings at the North American box office in 2019 amounted to $USD 11.32 billion according to Statista.com . In January 2020, the U.S. motion picture and sound recording industry employed over 456 thousand people, with several hundred thousand more in Canada, the U.K., and around the world.
As a result of production closures and cinema shutdowns related to COVID-19, the majority of the industry’s revenues and jobs have been temporarily lost and are now at significant risk of long-term damage if the industry is unable to find solutions that can provide for the safe resumption of operations.
Specifically, the global entertainment industry is projected to lose a staggering $160 billion of growth over the next five years, according to research firm Ampere Analysis .
On November 2nd, AMC Theatres announced a 91% drop in revenues during the most recent earnings period, with losses hitting $906 million in just this quarter.
LOOP AND DRAGANFLY FILM BUBBLE POSITIONED TO DELIVER INDUSTRY-LEADING SOLUTION
“With the whole world watching, including professional sports leagues and teams, college sports leagues and teams, world-renown venues and hospitality companies, Loop hit it out of the park and provided the world with the empirical data necessary to demonstrate our bubble solution is nothing short of world-class.”
Draganfly’s Vital Intelligence technology utilizes regular cameras to read vital signs such as Heart Rate, Respiratory Rate, and Sp02. The technology can help screen for infectious conditions, including COVID-19. The technology has been deployed on Drones and in Kiosks, along with an initial mobile API that has been implemented with several pilot customers.
Loop CEO Rob Anson added, “The film industry has been an obvious major opportunity for our Venue Bubble solution and this first Film Bubble will provide a great showcase for our film industry solution, as well as, additional opportunities for travel, venue, and various healthcare applications we have been working on.”
Draganfly Inc. (CSE: DFLY; OTCQB: DFLYF; FSE: 3U8) is the creator of quality, cutting-edge and software and systems that revolutionize the way organizations can do business and service their stakeholders. Recognized as being at the forefront of technology for over 22 years, Draganfly is an award-winning, industry-leading manufacturer and technology developer serving the public safety, agriculture, industrial inspections, security, and mapping and surveying markets. Draganfly is a company driven by passion, ingenuity, and the need to provide efficient solutions and first-class services to its customers around the world with the goal of saving time, money, and lives.
About Loop Insights
Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network.
This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 7:32 AM on Monday, December 14th, 2020
Announce the receipt of in excess of $5,500,000 from the exercise of warrants up to December 11, 2020
The proceeds were received over the past four trading days as a result of strong equity market support for the momentum demonstrated by the Company
It serves as an indication of the strength of Empower’s shareholder base and its following
Company is pleased to report that our new website has been launched to reflect the Company’s pillars of growth in 2021 and beyond
VANCOUVER BC / December 14, 2020 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through its clinics, telemedicine platforms and as a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and validating novel COVID-19 testing protocols for CE, FDA and Health Canada approval is pleased to announce the following:
RECEIPT OF $5,500,000 + FROM THE EXERCISE OF WARRANTS ALLOWS EMPOWER TO CONTINUE TO EXECUTE WITH INCREASED STRENGTH
Empower is pleased to announce the receipt of in excess of $5,500,000 from the exercise of warrants up to December 11, 2020. The proceeds were received over the past four trading days as a result of strong equity market support for the momentum demonstrated by the Company. It serves as an indication of the strength of Empower’s shareholder base and its following.
The Company expects to generate meaningful revenue from its current and anticipated sales pipeline over the next 12 months, as well as, receive additional proceeds from further anticipated warrant exercises, the Company is confident it has the war chest necessary to pursue numerous opportunities. KAI medical laboratory continues to expand nationwide in the U.S., Empower is growing physician services and direct access to patients through new clinics expansions and the company will provide dynamic technology-based healthcare services to meet patient needs.
Steven McAuley, Chairman and CEO of Empower stated, “The timing of these warrant exercises could not be better as we head into our biggest growth phase ever, thanks to rapidly growing demand for our KAI Medical Lab COVID-19 testing solutions, as well as, the impending launch of our FDA approved KAI Saliva Test plus the pending clinic group acquisition in Canada. These proceeds significantly bolster our financial strength, resources and confidence necessary to aggressively pursue our growth strategies in 2021.”
EMPOWER LAUNCHES NEW WEBSITE TO BETTER REFLECT COMPANY’S 2021 DIRECTION
The Company is pleased to report that our new website has been launched to reflect the Company’s pillars of growth in 2021 and beyond, as well as, our defined vision as follows:
GROWTH PILLARS
Health & Wellness Is Our Purpose – Through our clinics in the US and telemedicine platform, our physicians treat patients in Oregon, Arizona and Washington State. Within this section you can read our statements about integrated care and patient first care.
Diagnostics & Tech Is Our Vision – The October 5th acquisition of Texas-based KAI Medical Laboratory was a significant achievement for Empower, as it firmly and immediately established the science and research side of Empower. In its first month, KAI delivered record revenues and soon after announced its first $1,000,000 COVID-19 testing contract for a major film and television studio.
This section is rich in information for investors that want to better familiarize themselves with the capabilities of KAI Laboratory and COVID-19 testing capabilities that attracted major contracts and R&D initiatives.
EMPOWER TO COMMENCE VERIFIED DISCUSSIONS BY CEO AND KEY PERSONNEL ON AGORACOM
The Company is commencing discussions on its “CEO Verified Forum” on AGORACOM, which is intended to serve as one of the Company’s social media platforms for interaction with current and prospective shareholders.
Steven McAuley added “The growth experienced by Empower over the past 12 months has come from all sources providing the best possible engagement with our clients, followers, investors and all social platforms. I enjoy responding to shareholder inquiries, and the demand for engagement and discussion by investors has grown significantly. Engaging with Agoracom followers is an invaluable tool given our anticipated developments and I look forward to posting my comments and interactions with shareholders.”
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients and provide long term value for our shareholders.
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
Posted by AGORACOM-JC
at 7:27 AM on Monday, December 14th, 2020
Announces that it will begin to publicly disclose unaudited net asset value per share on a monthly basis, commencing with the January 31, 2021 period.
This expands on ThreeD’s established practice of releasing NAV on a quarterly basis and reflect our response to shareholder interest in receiving NAV information more frequently.
TORONTO, Dec. 14, 2020 – ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQB:IDKFF) announces that it will begin to publicly disclose unaudited net asset value per share (“NAV”) on a monthly basis, commencing with the January 31, 2021 period. This expands on ThreeD’s established practice of releasing NAV on a quarterly basis and reflect our response to shareholder interest in receiving NAV information more frequently.
Monthly NAV will be disclosed by the Company in a press release and be available on the Company’s website approximately 15 days after month-end. NAV will be calculated based on unaudited month-end financial information.
NAV is a non-GAAP measure calculated as the value of total assets less the value of total liabilities divided by total number of common shares outstanding, as at a specific date. The term NAV does not have any standardized meaning according to GAAP and therefore may not be comparable to similar measures presented by other companies.
“ThreeD believes that providing monthly NAV updates, will be beneficial to our shareholders by providing information that is useful to understanding our performance”, states Sheldon Inwentash, Chairman and CEO, “This measure will help provide a benchmark to evaluate our business relative to that of our peers”.
About ThreeD Capital Inc.
ThreeD is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors. ThreeD’s investment strategy is to invest in multiple private and public companies across a variety of sectors globally. ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services and access to the Company’s ecosystem.
For further information: Gerry Feldman, CPA, CA Chief Financial Officer and Corporate Secretary [email protected] Phone: 416-941-8900 ext 106
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
Forward-Looking Statements
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of Canadian securities laws including, without limitation, statements with respect to timing and content of future disclosures of the NAV of the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur including, without limitation, risks relating to the timing and content of future public disclosures by the Company or related to the fact that the term NAV does not have any standardized meaning according to GAAP and therefore may not be comparable to similar measures presented by other companies. Although the Company believes that the expectations reflected in the forward looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company’s actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.
Posted by AGORACOM-JC
at 3:38 PM on Friday, December 11th, 2020
Hollister Biosciences Inc. (HOLL:CSE) (HSTRF:OTC) (HOB: FRANKFURT) is a multi-state cannabis company with products in 230 dispensaries throughout California and over 80 dispensaries throughout Arizona, translating into the following great success:
REVENUES $CAD
Q1 $1,200,000
Q2 $11,500,000
Q3 $12,500,000
NOTE: Venom Extracts Acquisition Closed at the end of Q1.
TOTAL Q1/Q2/Q3
REVENUE $25.2M
On December 9 th, 2020, Venom achieved the second and final revenue milestone by generating in excess of CDN$40,000,000 of revenue calculated from January 1 st, 2020.
With the recent passage of Proposition 207 – legalizing the cultivation, sale and consumption of recreational cannabis in the state of Arizona Hollister is extremely well positioned to capitalize. This can best be summed up by quote of Venom Extracts Founder below:
“Seeing recreational Cannabis legalized in the state is an encouraging sign and is hopefully another step toward federal legalization. It should lead to increased tax revenue and job creation. The recreational cannabis market in Arizona could be valued at up to US $760 million by 2024 1 , significantly expanding the total addressable market for Cannabis in the state. We look forward to making our product line available to both the medical and recreational end user.” Shared Jacob Cohen, Founder of Venom Extracts, Hollister’s 100% owned subsidiary based in Arizona
In addition to organic sales, Hollister has several high-level partnerships that demonstrate how trusted the Company is within the industry, including:
Posted by AGORACOM-JC
at 3:12 PM on Friday, December 11th, 2020
Avicanna (AVCN: TSX) (AVCN: OTCQX) (0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.
Third Quarter Highlights
$882K in revenue, an increase of 24% from Q2-2020,
Double-digit growth, quarter over quarter from Q4-2019
In addition, the Company was able to reach a major milestone with the launch of certain products from its RHO Phyto product line in Canada and further diversified its revenue streams.
When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:
1. The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year.
2. Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain.
Recently Launched Medical Cannabis Program with its RHO Phyto™ Formulary Nationwide in Colombia (Read More)
Leveraging thesuccessful launch ofthe Company’sRHO Phyto™brandedadvancedmedical cannabisproduct linein Canada,the portfolio of preparations,including oil drops, sublingual sprays, capsules and topicals,are nowavailablenationwide inColombia through physician prescription.
The medical programincludesAvicanna’s 3pillarsaimed at setting the gold standard for medical cannabis in Colombia andotherLatin American markets, including
3. Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.
